Compare Ascendis Pharma A/S (ASND) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while iShares 3 7 Year Treasury Bond ETF trades at $116.44. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | IEI | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $120.72 |
52-Week Low | $189.74 | $116.16 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% on the day, amid a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a steady dividend payout schedule, with recent distributions around $0.37 per share. Market sentiment is influenced by rising Treasury yields and inflation concerns, as highlighted in recent financial news.
The outlook for IEI is cautious due to potential Federal Reserve rate hikes and inflation pressures, which could pressure bond prices. Opportunities lie in its government backing and lower volatility, but risks include interest rate sensitivity and macroeconomic shifts affecting yield curves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
